by Mr Mark Goyder
Sir, I am intrigued by the investor logic suggested by your report (May 1) that “other shareholders said that the City would not be influenced by concerns over what a deal would mean for AstraZeneca’s 7000 employees or the UK’s life sciences sector. We are not protectionist like the French. Commercial logic and price determines whether we back a deal or not.”
Institutional investors owe their fiduciary duty to their clients.
The wealth created for those clients depends on the creative abilities of a company’s employees. And clients will have corresponding investments across other companies in the life sciences sector. So if fund managers are truly promoting their clients’ interests, it is hard to see how they exclude the impact either on employees or on the sector from their assessment of “commercial logic”.
Unless, of course, those fund managers perceive commercial logic not as long-term wealth creation for their clients and beneficiaries, but the opportunity to crystallise immediate gains that help companies in their marketing and individuals in their performance bonuses.
Mark Goyder, Founder Director, Tomorrow’s Company
Published FT letters, May 5 2014
Read it in the FT here
Public procurement is too often solely made on price, and not enough on true value and to account for areas...
In January 2020, Tomorrow's Company co-hosted a major Financial Inclusion Summit, to launch our report into the role of employers...
Mental health in the workplace has gone from a fringe idea to being mainstream and top of the agenda in…
Dear Readers, Here are a few articles published in the last few days that address issues – such as mental…
We need a social contract that is fair, so that everyone has the chance to progress.
Joining Russell Goldsmith at the London offices of GSK to discuss this issue, were Kerry O'Callaghan, VP for Global Brand...
Tomorrow’s Company is proud to announce a partnership with the c suite podcast, a monthly show covering topics such as Marketing…
Press return to search